CFM Wealth Partners’s GSK GSK Stock Holding History

CFM Wealth Partners’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-557	Closed	-$27K	–	525
2020 Q1	$27K	Buy	+557	New	+$29.7K	0.01%	333

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

CFM Wealth Partners's GSK Position: Q2 2020 in Review

CFM Wealth Partners sold out of GSK (GSK) in Q2 2020, closing a stake of 557 shares — an estimated $27K sold.

CFM Wealth Partners first reported a position in GSK in Q1 2020 and held it in 1 quarter. The position peaked at $27K in Q1 2020. 840 funds tracked by Wall St. Rank hold GSK as of Q2 2020.

CFM Wealth Partners reported no remaining GSK position as of Q2 2020 after selling out during the quarter.
CFM Wealth Partners sold 557 GSK shares in Q2 2020, an estimated $27K.
CFM Wealth Partners first reported a position in GSK in Q1 2020 and held it in 1 quarter.
CFM Wealth Partners's GSK position peaked at $27K in Q1 2020.
840 funds tracked by Wall St. Rank held GSK as of Q2 2020.

Based on CFM Wealth Partners's 13F filing for Q2 2020, filed 14 Aug 2020.